Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Boston Examiner.
Press releases published on April 29, 2025
First Major U.S. Commercial Health Insurer Approves Purchase of ReWalk 7 Personal Exoskeleton
GlobeNewswire
·
April 29, 2025
Approval signals important progress in U.S. market expansion as major commercial health insurers begin to follow precedent set with Medicare reimbursement for personal exoskeletons established in 2024 Decision to cover device arrives shortly after the …
Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025
GlobeNewswire
·
April 29, 2025
CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, presented noteworthy new data at the American Association for Cancer …
Employ’s Latest Report on Job Seeker Insights Helps Recruiters Fine-Tune Processes, Personalize Outreach and Stay Ahead of Hiring Trends
GlobeNewswire
·
April 29, 2025
DENVER, April 29, 2025 (GLOBE NEWSWIRE) -- Employ Inc., the market-leading intelligent hiring suite, announces today the release of the 2025 Job Seeker Nation report, providing a data-driven look into how job seekers perceive the market, candidates’ …
Solid Biosciences to Present at the American Society of Gene and Cell Therapy’s 28th Annual Meeting
GlobeNewswire
·
April 29, 2025
CHARLESTOWN, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial …
Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF)
GlobeNewswire
·
April 29, 2025
WATERTOWN, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious …
Repligen Reports First Quarter 2025 Financial Results
GlobeNewswire
·
April 29, 2025
Revenue of $169 million, year-over-year increase of 10% as reported and 14% organic non-COVID growth Orders increased sequentially and high-teens year-over-year Adjusted operating income increased 72% year-over-year Reiterates 2025 full year organic …
Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States
GlobeNewswire
·
April 29, 2025
CLN-978 is the first and only development-stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases Sjögren’s disease represents the third indication under development for CLN-978, and is a disease with high unmet need and no …
Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences
GlobeNewswire
·
April 29, 2025
BEDFORD, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific …
Headwall Group and Laitram Machinery Announce Deployment of Hyperspectral Technology in Food Processing
GlobeNewswire
·
April 29, 2025
Bolton, Massachusetts …